Guardant Health, Inc. $GH Shares Acquired by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. increased its position in Guardant Health, Inc. (NASDAQ:GH) by 1,534.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 38,355 shares of the company’s stock after buying an additional 36,008 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Guardant Health were worth $4,163,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in GH. AQR Capital Management LLC raised its position in shares of Guardant Health by 56.5% in the 1st quarter. AQR Capital Management LLC now owns 71,534 shares of the company’s stock worth $3,012,000 after buying an additional 25,831 shares during the period. Empowered Funds LLC purchased a new position in shares of Guardant Health in the 1st quarter worth $274,000. Sei Investments Co. raised its position in shares of Guardant Health by 15.8% in the 2nd quarter. Sei Investments Co. now owns 77,308 shares of the company’s stock worth $4,023,000 after buying an additional 10,538 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Guardant Health by 9.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 632,630 shares of the company’s stock worth $32,922,000 after buying an additional 54,284 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Guardant Health by 56.4% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 111,445 shares of the company’s stock worth $5,800,000 after buying an additional 40,209 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Guardant Health news, Director Ian T. Clark sold 6,876 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $106.90, for a total value of $735,044.40. Following the transaction, the director directly owned 2,975 shares of the company’s stock, valued at $318,027.50. This trade represents a 69.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider John G. Saia sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $106.51, for a total value of $2,130,200.00. Following the completion of the transaction, the insider directly owned 45,950 shares in the company, valued at $4,894,134.50. This trade represents a 30.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 296,838 shares of company stock valued at $31,878,906 over the last ninety days. Insiders own 5.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on GH. Piper Sandler set a $127.00 target price on Guardant Health in a research report on Thursday. Stifel Nicolaus increased their target price on Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. Wells Fargo & Company increased their target price on Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, February 20th. BTIG Research increased their target price on Guardant Health from $140.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. Finally, Leerink Partners increased their target price on Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a research report on Friday, February 20th. Nineteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Guardant Health presently has a consensus rating of “Moderate Buy” and an average price target of $129.00.

Guardant Health Price Performance

NASDAQ:GH opened at $118.95 on Monday. The business’s 50-day moving average is $91.15 and its two-hundred day moving average is $98.94. Guardant Health, Inc. has a 12 month low of $36.36 and a 12 month high of $121.01. The firm has a market capitalization of $15.77 billion, a PE ratio of -35.09 and a beta of 1.48.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The business had revenue of $281.27 million during the quarter, compared to the consensus estimate of $269.74 million. During the same quarter in the previous year, the business earned ($0.62) earnings per share. Guardant Health’s revenue for the quarter was up 39.4% compared to the same quarter last year. Equities analysts anticipate that Guardant Health, Inc. will post -2.92 EPS for the current year.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.